BioAxone is a clinical-stage biopharmaceutical company that is transforming treatments for neurotrauma and neurovascular disorders. The company has developed innovative therapies based on a deep understanding of axon regeneration and neuronal signaling pathways.
BioAxone has an IND-ready ROCK-2 selective, oral kinase inhibitor, BA-1049, for treatment of neurovascular disorders. ROCK2 signaling is overactivated in endothelial ...
BioAxone is a clinical-stage biopharmaceutical company that is transforming treatments for neurotrauma and neurovascular disorders. The company has developed innovative therapies based on a deep understanding of axon regeneration and neuronal signaling pathways.
BioAxone has an IND-ready ROCK-2 selective, oral kinase inhibitor, BA-1049, for treatment of neurovascular disorders. ROCK2 signaling is overactivated in endothelial cells in hereditary angioma, a disease where benign vascular malformations are “leaky” and can cause stroke. Similarly, in acute ischemic stroke, ROCK2 is hyperactivated in brain vascular endothelial cells.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.